Phenotypic impact of deregulated expression of class I histone deacetylases in urothelial cell carcinoma of the bladder

Molecular Carcinogenesis

Volumn 54, Issue 7, 2015, Pages 523-531

  Junqueira Neto, Susana ^a   Vieira, Filipa Q ^a,b   Montezuma, Diana ^a   Costa, Natália R ^a   Antunes, Luís ^a   Baptista, Tiago ^a   Oliveira, Ana Isabel ^a   Graça, Inês ^a,b   Rodrigues, Ângelo ^a   Magalhães, José S ^a   Oliveira, Jorge ^a   Henrique, Rui ^a,c   Jerónimo, Carmen ^a,c  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Apoptosis; Bladder cancer; Class I HDACs; Viability

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE; SMALL INTERFERING RNA;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; BLADDER UROTHELIAL CELL CARCINOMA; CANCER PROGNOSIS; CANCER SURVIVAL; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; BLADDER; BLADDER TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; MALE; MIDDLE AGED; RNA INTERFERENCE; RNA, SMALL INTERFERING; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84930754725     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22117     Document Type: Article

References (44)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-2917. Epub 2011/02/26.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90. Epub 2011/02/08.
3. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374:239-249. Epub 2009/06/13.
4. Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 2000; 27:1-13, vii. Epub 2000/03/04.
5. Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 2009; 4:251-285. Epub 2008/10/09.
6. Rodrigues A, Henrique R, Jerónimo C. Bladder cancer pathology (ChapterKey 306590). In: Schwab M, editor. Encyclopedia of cancer. Heidelberg, Germany: Springer; 2012.
7. Falke J, Witjes JA. Contemporary management of low-risk bladder cancer. Nat Rev Urol 2011; 8:42-49. Epub 2011/01/14.
8. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54:784-788. Epub 1994/02/01.
9. Oliveira AI, Jeronimo C, Henrique R. Moving forward in bladder cancer detection and diagnosis: The role of epigenetic biomarkers. Expert Rev Mol Diagn 2012; 12:871-878. Epub 2012/12/20.
10. Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003; 63:8108-8112. Epub 2003/12/18.
11. Sidransky D, Von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991; 252:706-709. Epub 1991/05/03.
12. Hernandez S, Lopez-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006; 24:3664-3671. Epub 2006/08/01.
13. Catto JW, Miah S, Owen HC, et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 2009; 69:8472-8481. Epub 2009/10/22.
14. Yates DR, Rehman I, Abbod MF, et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 2007; 13:2046-2053. Epub 2007/04/04.
15. Di Marcotullio L, Canettieri G, Infante P, Greco A, Gulino A. Protected from the inside: Endogenous histone deacetylase inhibitors and the road to cancer. Biochim Biophys Acta 2011; 1815:241-252. Epub 2011/02/01.
16. Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 2007; 76:75-100. Epub 2007/03/17.
17. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J 2003; 370:737-749. Epub 2002/11/14.
18. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1:19-25. Epub 2007/06/01.
19. Reichert N, Choukrallah MA, Matthias P. Multiple roles of class I HDACs in proliferation, differentiation, and development. Cell Mol Life Sci 2012; 69:2173-2187. Epub 2012/01/31.
20. Delcuve GP, Khan DH, Davie JR. Roles of histone deacetylases in epigenetic regulation: Emerging paradigms from studies with inhibitors. Clin Epigenet 2012; 4:5. Epub 2012/03/15.
21. Weichert W, Roske A, Gekeler V, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008; 98:604-610. Epub 2008/01/24.
22. Weichert W, Roske A, Niesporek S, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: Specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008; 14:1669-1677. Epub 2008/03/19.
23. Weichert W, Roske A, Gekeler V, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: A retrospective analysis. Lancet Oncol 2008; 9:139-148. Epub 2008/01/22.
24. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007; 26:5420-5432. Epub 2007/08/19.
25. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 2001; 1:194-202. Epub 2002/03/21.
26. Huang BH, Laban M, Leung CH, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005; 12:395-404. Epub 2005/01/25.
27. Glaser KB, Li J, Staver MJ, et al. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 2003; 310:529-536. Epub 2003/10/03.
28. Senese S, Zaragoza K, Minardi S, et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 2007; 27:4784-4795. Epub 2007/05/02.
29. Harms KL, Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 2007; 67:3145-3152. Epub 2007/04/06.
30. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett 2009; 277:8-21. Epub 2008/10/01.
31. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009; 280:168-176. Epub 2008/12/24.
32. Ozawa A, Tanji N, Kikugawa T, et al. Inhibition of bladder tumour growth by histone deacetylase inhibitor. BJU Int 2010; 105:1181-1186. Epub 2009/08/18.
33. Netto GJ. Molecular biomarkers in urothelial carcinoma of the bladder: Are we there yet? Nat Rev Urol 2012; 9:41-51. Epub 2011/12/14.
34. Zhang Z, Yamashita H, Toyama T, et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat 2005; 94:11-16. Epub 2005/09/21.
35. Van Damme M, Crompot E, Meuleman N, et al. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics 2012; 7:1403-1412. Epub 2012/10/31.
36. Hassler MR, Egger G. Epigenomics of cancer-Emerging new concepts. Biochimie 2012; 94:2219-2230.
37. Jung KH, Noh JH, Kim JK, et al. HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. J Cell Biochem 2012; 113:2167-2177. Epub 2012/04/12.
38. Lagger G, O'Carroll D, Rembold M, et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002; 21:2672-2681. Epub 2002/05/29.
39. Yamaguchi T, Cubizolles F, Zhang Y, et al. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev 2010; 24:455-469. Epub 2010/03/03.
40. Lin KT, Yeh SH, Chen DS, Chen PJ, Jou YS. Epigenetic activation of alpha4, beta2 and beta6 integrins involved in cell migration in trichostatin A-treated Hep3B cells. J Biomed Sci 2005; 12:803-813. Epub 2005/09/01.
41. Hayashi A, Horiuchi A, Kikuchi N, et al. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int J Cancer 2010; 127:1332-1346. Epub 2010/01/06.
42. Zupkovitz G, Tischler J, Posch M, et al. Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol Cell Biol 2006; 26:7913-7928. Epub 2006/08/31.
43. Dovey OM, Foster CT, Cowley SM. Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation. Proc Natl Acad Sci USA 2010; 107:8242-8247. Epub 2010/04/21.
44. Jurkin J, Zupkovitz G, Lagger S, et al. Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle 2011; 10:406-412. Epub 2011/01/29.